J 2023

Clinical presentation and pulmonary function tests in post-acute COVID-19 patients

GENZOR, Samuel, Petr JAKUBEC, Milan SOVA, Jan MIZERA, Pavol JOPPA et. al.

Základní údaje

Originální název

Clinical presentation and pulmonary function tests in post-acute COVID-19 patients

Autoři

GENZOR, Samuel (203 Česká republika), Petr JAKUBEC (203 Česká republika), Milan SOVA (203 Česká republika, domácí), Jan MIZERA (203 Česká republika), Pavol JOPPA (703 Slovensko), Radim BURGET (203 Česká republika) a Pavol POBEHA (703 Slovensko)

Vydání

Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2023, 1213-8118

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 0.900 v roce 2022

Kód RIV

RIV/00216224:14110/23:00130052

Organizační jednotka

Lékařská fakulta

UT WoS

000863250600001

Klíčová slova anglicky

COVID-19; post-acute phase; clinical presentation; pulmonary function tests

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 26. 1. 2024 10:18, Mgr. Tereza Miškechová

Anotace

V originále

Aims. The study analysed post-acute COVID-19 symptoms and the pulmonary function test (PFT) results in patients surviving the native strain of the virus. Methods. The study was prospective; the inclusion criteria were positive PCR test for SARS-CoV-2 and age 18-100. Exclusion criteria were active respiratory infection, known or suspicious pre-existing pulmonary disease, cardiac failure, recent or acute pulmonary embolism, anaemia, and neuromuscular diseases. The recruitment period was 1st March 2020 - 25th December 2020. The initial examination was performed 4-12 weeks after the disease onset. All subjects underwent physical examination, anamnesis, chest x-ray and PFT. Results. The study involved 785 subjects (345 male) mean age 53.8 (SD 14.6). The disease severity groups were: mild (G1), moderate (G2) and severe/critical (G3). Anosmia was present in the acute disease phase in 45.2% of G1 patients, but only in 4.5% of G3 patients. Dyspnoea occurred frequently in more severe groups (40%, 51.8% and 63.7% for G1, G2 and G3 respectively), while cough and fatigue showed no relationship to disease severity. Females were more likely to experience persistent symptoms. PFT results were significantly decreased in more severe groups compared to the mild COVID-19 patients, diffusing capacity was 86.3%, 79% and 68% of predicted values in G1, G2 and G3 respectively. Conclusion. Anosmia during the acute phase was associated with mild disease, persisting dyspnoea was more frequent after more severe COVID-19. Females tended to have persisting symptoms in post-acute phase more frequently. PFT results showed decrease with disease severity.